4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001193125-26-061712
Chief Executive Officer sold 6,967 shares at $52.58 ($366,325)
- Chief Executive Officer acquired 13,250 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Kulkarni Samarth · Chief Executive Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-18 | Exercise or conversion : show line 1 in the form | +13,250 | 233,073 | D | ||
| 2026-02-19 | Sale : show line 2 in the form | −6,967 | $52.58 | $366,325 | 226,106 | D |
| Open-market sales · 6,967 sh · avg $52.58 · $366,325 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-02-18 | Exercise or conversion : show line 3 in the form Restricted Stock Units | −13,250 | 0 | D |
Loading xslF345X05/ownership.xml…